Key Points
- Curaleaf Holdings has publicly unveiled an acquisition proposal for Aurora Cannabis valued at US$4.00 per share
- The proposal represents a 45% premium above Aurora’s 30-day volume weighted average trading price of US$2.75
- Each Aurora share would receive 0.3463 Curaleaf shares combined with US$0.75 in cash
- ACB shares climbed 18% following the announcement, reaching approximately $4.76
- Aurora’s board twice declined private acquisition discussions initiated by Curaleaf on June 23 and July 7, 2026
Following Aurora Cannabis’s refusal to participate in confidential negotiations, Curaleaf Holdings has made its acquisition proposal public, offering US$4.00 per share directly to shareholders.
The announcement on Tuesday triggered a surge of over 18% in ACB shares during trading sessions, with the stock reaching $4.76. Even before market opening, pre-market activity indicated a 15% gain.
Under the proposed terms, Aurora shareholders would receive a combination of 0.3463 Curaleaf subordinate voting shares alongside US$0.75 cash per share held. Based on current market values, this package equals the US$4.00 per share offer price.
Compared to Aurora’s 30-day volume weighted average price of US$2.75, the proposal includes a 45% premium. When measured against Monday’s closing price, the premium stands at 38%.
A protective mechanism caps the equity component of the deal. Should Curaleaf’s share price appreciate significantly before closing, the stock consideration will be adjusted to ensure the total value doesn’t surpass US$5.00 per Aurora share, calculated using Curaleaf’s 20-day VWAP.
According to Curaleaf, initial contact with Aurora’s executive team occurred on June 23, 2026, with a follow-up attempt made on July 7, 2026. Aurora’s board rejected engagement on both occasions.
Curaleaf’s CEO Boris Jordan expressed frustration with the situation. “We approached Aurora privately and constructively on multiple occasions,” Jordan stated. “We were very disappointed that the Board refused to meaningfully engage.”
Jordan explained the company would now appeal directly to Aurora’s investor base, describing the premium as “compelling” while characterizing additional delays as “unjustified.”
Financial Profile of Merged Entity
A successful combination would create an organization generating over US$1.5 billion in trailing twelve-month revenue with approximately US$350 million in adjusted EBITDA during the same timeframe.
Curaleaf projects minimum annual cost savings of US$40 million through operational synergies resulting from the transaction.
Deal Structure and Key Dates
A formal tender offer has not yet been submitted. Curaleaf has emphasized that completion of the proposed transaction cannot be guaranteed.
The company reserves the right to terminate discussions upon discovering materially adverse facts about Aurora, if Aurora employs defensive measures, or if Aurora finalizes alternative deals.
Should the formal bid proceed, it would stay active for 105 days. Notably, the proposal excludes due diligence and financing contingencies, eliminating two frequent obstacles to deal completion.
Complete tender offer documentation will be submitted to Canadian securities authorities and the U.S. Securities and Exchange Commission when the official bid commences.
Canaccord Genuity has been retained as Curaleaf’s financial advisor for this transaction. Dentons is providing legal representation.
ACB closed the session at $4.76, representing an increase of $0.73, or 18.11%.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
